 {#all13629-sec-0001}

To the Editor,

Improvements in asthma outcomes have stalled over the past decade,[1](#all13629-bib-0001){ref-type="ref"} which may be attributed to treating patients on the basis of a generic diagnostic label. The taxonomy "Treatable Traits" was proposed by Agusti et al (2016) as a precision medicine approach for the diagnosis and management of chronic airway diseases that is based on the identification of genetic, phenotypic and psychosocial characteristics for which therapeutic interventions are known to improve respiratory health.[2](#all13629-bib-0002){ref-type="ref"} The Unbiased Biomarkers for the Prediction of Respiratory Disease Outcomes (U‐BIOPRED) project was set up to identify multidimensional phenotypes and endotypes in severe asthma.[3](#all13629-bib-0003){ref-type="ref"} Here, we aim to identify and quantify treatable traits within the severe and mild/moderate U‐BIOPRED adult asthma cohorts[3](#all13629-bib-0003){ref-type="ref"} and across previously identified phenotypes.[4](#all13629-bib-0004){ref-type="ref"} We hypothesize that treatable traits will be more common in severe asthma and vary significantly across asthma phenotypes.

Data from the severe asthma and mild/moderate asthma cohorts of the U‐BIOPRED project were included in this study. Full details of the study population and methodology have been presented elsewhere.[3](#all13629-bib-0003){ref-type="ref"} Criteria for treatable traits were based on Agusti et al[2](#all13629-bib-0002){ref-type="ref"} and presented in Table [1](#all13629-tbl-0001){ref-type="table"}. Chi‐squared tests were used to examine differences in the prevalence of each treatable trait between groups and independent sample t tests used to determine differences in the total number of traits between cohorts. No adjustment for multiple testing was applied as the analyses were considered exploratory; as this may inflate the type‐1 error rate, individual *P* values are presented for each comparison. A post hoc power calculation shows our sample of 421 (severe smoking/ex‐smoking vs severe nonsmoking) and 399 (severe nonsmoking vs mild/moderate) is sufficient to identify a difference in treatable trait prevalence between cohorts with a medium effect size (0.3) and a power close to 1.00. Data analysis was supported by IBM SPSS Statistics for Windows, Version 24.0. Armonk, NY, USA, with significance set at *P* \< 0.05, unless otherwise stated.

###### 

Treatable traits and defining criteria

  Treatable trait category   Treatable trait                         Defining criteria
  -------------------------- --------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------
  Pulmonary                  Fixed airflow limitation                Postbronchodilator FEV~1~/FVC \< 0.7
                             Bronchodilator reversibility            Postbronchodilator increase in FEV~1~ [*AND/OR*]{.ul} FVC ≥12% [*AND*]{.ul} ≥200 ml
                             Type 2 inflammation                     Sputum eosinophil count ≥ 2% [*AND/OR*]{.ul} blood eosinophils ≥ 450 cells per ul [*AND/OR*]{.ul} FeNO \> 50 ppb
                             Neutrophilic inflammation               Sputum neutrophil count \> 60%
                             Cough                                   Asthma Quality of Life Questionnaire (AQLQ) Question 12 score ≤ 4 [*AND/OR*]{.ul} Sino‐Nasal Outcomes Test (SNOT‐20) Question score 4 ≥ 3
                             Exercise‐induced respiratory symptoms   Medical history finding of "routine physical activity and/or physical exercise as asthma trigger"
                             Bronchitis                              Medical history finding of "Current [*AND/OR*]{.ul} chronic bronchitis"
  Extra‐pulmonary            Rhinosinusitis                          Medical history finding of "Allergic/Non‐allergic rhinitis active AND/OR sinusitis active"
                             Nasal polyps                            Medical history finding of "Nasal polyps active"
                             Obese                                   BMI \> 30
                             Underweight                             BMI \< 18.5
                             Obstructive sleep apnoea                Epworth sleepiness scale score ≥ 11
                             Reflux                                  Medical history finding of "Reflux active"
                             Vocal cord dysfunction                  Medical history finding of "Vocal Cord Dysfunction active"
                             Osteoporosis                            Medical history finding of "Osteoporosis active"
                             Cardiovascular disease                  Medical history finding of "Coronary disease active"
                             Eczema                                  Medical history finding of "Eczema active"
                             Atopic                                  Positive skin prick test AND/OR blood IgE result
  Behavioural/psychosocial   Smoking                                 Medical history finding of "Current smoker"
                             Poor medication adherence               Medication Adherence Rating Scale (MARS) mean score \<4.5
                             Psychiatric disease                     Medical history finding of "Psychiatric disease active"
                             Depression                              Hospital Anxiety and Depression (HADS) depression domain score ≥ 11
                             Anxiety                                 Hospital Anxiety and Depression (HADS) anxiety domain score ≥ 11

Treatable traits presented here are based on that of Agusti et al.[2](#all13629-bib-0002){ref-type="ref"} BMI, body mass index; FeNO, fraction of exhaled nitric oxide; FEV~1~, forced expiratory volume in 1 second; FVC, forced vital capacity.
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2. PREVALENCE OF TREATABLE TRAITS {#all13629-sec-0002}
=================================

Twenty‐three treatable traits were identified, including seven pulmonary, 11 extra‐pulmonary and five behavioural/psychosocial treatable traits (Table [2](#all13629-tbl-0002){ref-type="table"}). Seven out of the ten most prevalent traits in severe asthma were classed as pulmonary treatable traits. The most prevalent extra‐pulmonary traits were as follows: atopy, rhinosinusitis, obesity, reflux and obstructive sleep apnoea. Poor adherence to medication, anxiety and depression were the most common behavioural/psychosocial treatable traits in severe asthma.

###### 

Frequency of treatable traits in severe and mild/moderate asthma, ordered by trait category and then trait frequency in severe asthma cohort

  Trait category             Treatable trait                                Severe asthma (combined)   Severe smoking/ex‐smoking asthma   Severe nonsmoking asthma   Mild/moderate nonsmoking asthma   Severe smoking/ex‐smoking vs severe nonsmoking asthma   Mild/moderate vs severe nonsmoking
  -------------------------- ---------------------------------------------- -------------------------- ---------------------------------- -------------------------- --------------------------------- ------------------------------------------------------- ------------------------------------
                             Subjects, n                                    421                        110                                311                        88                                                                                        
  Pulmonary                  Exercise‐induced respiratory symptoms, n (%)   352/421 (84)               91/110 (83)                        261/311 (84)               56/88 (64)                        *P* = 0.085                                             *P* \< 0.001
                             Cough, n (%)                                   246/387 (64)               65/98 (66)                         181/289 (63)               19/87 (22)                        *P* = 0.511                                             *P* \< 0.001
                             Fixed airflow limitation, n (%)                245/415 (59)               73/109 (67)                        172/306 (56)               17/85 (20)                        *P* = 0.050                                             *P* \< 0.001
                             Bronchodilator reversibility, n (%)            244/415 (59)               74/109 (68)                        170/306 (56)               33/85 (39)                        *P* = 0.025                                             *P* = 0.006
                             Bronchitis, n (%)                              214/421 (51)               57/110 (52)                        157/311 (51)               16/88 (18)                        *P* = 0.810                                             *P* \< 0.001
                             Type 2 inflammation, n (%)                     184/421 (44)               50/110 (45)                        134/311 (43)               30/88 (34)                        *P* = 0.667                                             *P* = 0.130
                             Neutrophilic inflammation, n (%)               73/181 (40)                20/53 (38)                         53/128 (41)                13/43 (30)                        *P* = 0.647                                             *P* = 0.193
  Extra‐pulmonary            Atopic, n (%)                                  298/421 (71)               68/110 (62)                        230/311 (74)               79/88 (90)                        *P* = 0.016                                             *P* = 0.002
                             Rhinosinusitis, n (%)                          204/421 (48)               48/110 (44)                        156/311 (50)               35/88 (40)                        *P* = 0.239                                             *P* = 0.085
                             Obese, n (%)                                   164/421 (39)               44/110 (40)                        120/311 (39)               16/88 (18)                        *P* = 0.794                                             *P* \< 0.001
                             Reflux, n (%)                                  152/421 (36)               50/110 (46)                        102/311 (33)               10/88 (11)                        *P* = 0.018                                             *P* \< 0.001
                             Obstructive sleep apnoea, n (%)                95/372 (26)                26/95 (27)                         69/277 (25)                9/85 (11)                         *P* = 0.635                                             *P* = 0.005
                             Osteoporosis, n (%)                            94/421 (22)                24/110 (22)                        70/311 (23)                3/88 (3)                          *P* = 0.881                                             *P* \< 0.001
                             Eczema, n (%)                                  76/421 (18)                19/110 (17)                        57/311 (18)                10/88 (11)                        *P* = 0.805                                             *P* = 0.123
                             Nasal polyps, n (%)                            58/421 (14)                14/110 (13)                        44/311 (14)                1/88 (1)                          *P* = 0.710                                             *P* = 0.001
                             Vocal cord dysfunction, n (%)                  17/421 (4)                 5/110 (5)                          12/311 (4)                 1/88 (1)                          *P* = 0.753                                             *P* = 0.204
                             Cardiovascular disease, n (%)                  9/421 (2)                  5/110 (5)                          4/311 (1)                  0/88 (0)                          *P* = 0.042                                             *P* = 0.285
                             Underweight, n (%)                             2/421 (1)                  0/110 (0)                          2/311 (1)                  2/88(2)                           *P* = 0.399                                             *P* = 0.175
  Behavioural/psychosocial   Poor medication adherence, n (%)               147/372 (40)               38/94 (40)                         109/278 (39)               44/84 (52)                        *P* = 0.835                                             *P* = 0.032
                             Anxiety, n (%)                                 65/295 (22)                16/72 (22)                         49/223 (22)                4/70 (6)                          *P* = 0.965                                             *P* = 0.002
                             Depression, n (%)                              39/295 (13)                13/72 (18)                         26/223 (12)                2/70 (3)                          *P* = 0.164                                             *P* = 0.029
                             Smoking, n (%)                                 42/421 (10)                42/110 (38)                        ‐                          ‐                                 ‐                                                       ‐
                             Psychiatric disease, n (%)                     32/421 (8)                 14/110 (13)                        18/311 (6)                 0/88 (0)                          *P* = 0.018                                             *P* = 0.021

Data are expressed as n/N (%). Differences between cohorts determined using Chi‐squared test.
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3. DIFFERENCES IN TREATABLE TRAITS ACROSS ASTHMA COHORTS {#all13629-sec-0003}
========================================================

The severe smoking/ex‐smoking asthma cohort displayed on average one more treatable trait than the severe nonsmoking asthma cohort (8 ± 3 vs 7 ± 2, *P* = 0.007). Differences in the prevalence of individual traits, all higher in the smoking/ex‐smoking cohort, were seen in bronchodilator reversibility, fixed airflow limitation (*P* = 0.050), reflux, cardiovascular disease and psychiatric disease. Only atopy was higher in prevalence in the nonsmoking cohort.

Nonsmoking individuals with severe asthma have more treatable traits than nonsmoking individuals with mild/moderate asthma (7 ± 2 vs 5 ± 2, *P* \< 0.001). Likewise, individual treatable traits were generally more common in nonsmoking severe asthma compared to the mild/moderate asthma cohort. Only in atopy and poor medication adherence was the prevalence of the treatable trait significantly higher in mild/moderate asthma. The prevalence of treatable traits across previously identified clusters[4](#all13629-bib-0004){ref-type="ref"} is presented and discussed on the Appendix [S1](#all13629-sup-0001){ref-type="supplementary-material"}.

4. DISCUSSION {#all13629-sec-0004}
=============

The identification of treatable traits facilitates a precision medicine strategy for the management of airways disease, that is free from the traditional diagnostic labels and based on the identification of pulmonary, extra‐pulmonary and psychosocial characteristics, for which there are evidence‐based therapeutic choices. This proposal was recently supported by the *Lancet* commission "After asthma: redefining airways disease"[5](#all13629-bib-0005){ref-type="ref"} and was a favoured strategy to move the field towards precision medicine at a research seminar, held at the European Respiratory Society\'s annual meeting.[6](#all13629-bib-0006){ref-type="ref"} Ours is the first study to apply the concept to a large asthma cohort, and we have identified a plethora of pulmonary, extra‐pulmonary and behavioural / psychosocial treatable traits. The prevalence of treatable traits, both pulmonary and nonpulmonary, was generally higher in individuals with severe asthma compared to mild/moderate asthma. We also identified a difference in the prevalence of pulmonary treatable traits across clinical clusters of patients. Approximately 5%‐10% of asthmatics remain poorly controlled, despite being prescribed the maximum dose of therapy.[7](#all13629-bib-0007){ref-type="ref"} Our data suggest individuals with severe asthma, who remain symptomatic despite receiving a high dose ICS, display on average seven treatable traits, and therefore present multiple treatment opportunities beyond the traditional stepwise approach.

Perhaps unsurprisingly, pulmonary traits accounted for seven of the ten most prevalent treatable traits in our asthma cohorts and were generally more common in severe asthma. Interestingly, however, we also observed an increased prevalence of extra‐pulmonary and behavioural/psychosocial traits in severe asthma suggesting an association with asthma severity, which may reflect the impact of living with severe chronic respiratory conditions. Our data highlight that multiple treatment opportunities exist beyond the pulmonary system, and a holistic management strategy, such as the treatable trait approach, may be beneficial to both physical and mental well‐being.

This is the first study to apply the concept of treatable traits to a large asthma cohort. Several limitations are worthy of discussion; firstly, we utilized the original paper on treatable traits,[2](#all13629-bib-0002){ref-type="ref"} treatment guidelines and clinical experience to determine the classification criteria for our treatable traits. We acknowledge that our list of traits is not exhaustive and that the selected criteria for some traits could be contentious. Prospective studies would benefit from additional paraclinical investigations to determine the prevalence of additional treatable traits, for example ventilation heterogeneity and small airway disease. Finally, we acknowledge that some traits may not be mutually exclusive and some maybe modified by asthma treatment. Associations between traits were not explored here but have been discussed elsewhere.[8](#all13629-bib-0008){ref-type="ref"}

In conclusion, the label‐free, precision medicine approach provided by the treatable traits construct allowed for the identification of multiple treatment opportunities for patients with asthma, beyond the traditional stepwise approach. We eagerly await the results of prospective, longitudinal, clinical trials to determine whether this translates to improved clinical outcomes for individuals with respiratory disease.
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